Eiger BioPharmaceuticals (NASDAQ:EIGR) completed enrollment of the Phase 2 ULTRA study designed to evaluate the effects of ubenimex in patients with primary and secondary lymphedema of the lower limbs. A total of 54 patients were enrolled across sites in the U.S. and Australia.Read More
Microbix Biosystems (TSX:MBX) has signed a distribution agreement with Meridian Life Science, a wholly owned unit of Meridian Bioscience (NASDAQ:VIVO), a fully integrated global diagnostic and life sciences company.Read More
Rodman & Renshaw has initiated coverage of LabStyle Innovations (NASDAQ:DRIO) with a “buy” rating and $12 price target. The stock closed at $5.40 on Friday.
LabStyle is an emerging digital health company focused on the monitoring and management of diabetes.Read More
Dipexium Pharmaceuticals (NASDAQ:DPRX) said that Australia and New Zealand have issued new Locilex patents, with expiry dates in June 2033.
The patents’ claims are directed to a novel formulation of Locilex, an antibiotic peptide formulated as a topical cream, and use of Locilex as a method of treating skin or wound infections.Read More